Warfarin Pharmacogenetic Screen
Also known as: CYP2C9, VKORC1« Back to test list
Variants in the CYP2C9 and VKORC1 genes modify the rate at which the anti-coagulant medication, warfarin, is broken down in the body. A patient with such variants may be at risk of toxicity from the medication.
This tests is useful to guide dosage prior to and within the first month of warfarin therapy.
This test has a role in identifying patients who may benefit from avoiding a specific drug or dose, but it provides little useful information for people (including relatives) who are not taking the medications of concern. Testing of relatives is generally not recommended.
The laboratory report describes the gene variants detected in a patient, and the implications regarding drug choice or dose.
Analysis of the CYP2C9 and VKORC1 genes.
This test can be requested by any medical practitioner.
5 mL blood in EDTA. Specimens may be collected by the requesting practitioner or at any Sonic Healthcare pathology collection centre.
To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.
We also recommend that the patient or another adult check the labelling of request forms and sample tubes.
Please list current and proposed medications on the request form. Please highlight any medications that have caused problems in the past.